Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-valent pneumococcal conjugate vaccine lot-to-lot consistency in 2–5-year-old children
CTR20220983Phase 4Completed
- Sponsor
- Yuxi Watson Biotechnology
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal disease, sponsored by Yuxi Watson Biotechnology. Started Apr 2022; status: completed.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20220983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220983.